Applications for this meeting must be submitted by July 6, 2014. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the Conference Chair if more seats become available due to cancellations.
This conference will focus on rare cells in circulation with a focus on human disease. Epithelial progenitor and stem cells, mesenchymal cells, fetal cells, and circulating tumor cells are normally relegated to extravascular organs but can traffic within the blood stream to initiate a number of important biological processes, such as organ repair and regeneration, angiogenesis, and metastasis. Thus, these cells represent a critically important population within the circulation and can provide a unique view into organ status, fetal health, and disease evolution. However, given their rarity within the circulation, the study of these cells poses unique challenges that will require innovative multi-disciplinary approaches.
To catalyze this embryonic field, we will bring together engineers, biologists, and clinicians to address the wide range of interest in these rare cell populations. The first conference will focus on cancer-relevant cells, primarily circulating tumor cells, including capture technology, definition of the population, correlation with disease diagnosis and progression, functional and molecular characterization, and relation to therapy.
A list of preliminary session topics and speakers is displayed below (discussion leaders, where known, are noted in italics). The detailed program is currently being developed by the Conference Chair and will be available by April 3, 2014. Please check back for updates.
- Translating Circulating Tumor Cell (CTC) Capture Technologies for Widespread Clinical Use
(Shannon Stott / Leon Terstappen)
- Dissemination and Self-Seeding: New Insights into the Role of Circulating Cells
(Max Wicha / Dario Marchetti)
- What Do CTCs Tell Us About the Pre-Metastatic Niche?
(Thea Tlsty / Tony Hollingsworth)
- Prognosis with CTCs: Getting Beyond Hazard Ratio and Kaplan-Meier
(David Nanus / Daniel Danila)
- Can CTCs Be Used to Diagnose and Stage Cancer?
(Stefanie Jeffrey / Anirban Maitra)
- Can CTCs and Progenitor Cells Inform Surgical and Medical Treatment?
(Linda Vahdat / Sofia Merajver)
- Mining Molecular Analyses of CTCs
- Interaction of Chemotherapy with CTCs
(Stuart Martin / Paraskevi Giannakakou)
- EMT: Phenotypic Changes and its Effect on CTC Data and its Interpretation